- Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Oncternal Therapeutics’ drug shows positive effect in CIRLL trial

CIRLL Phase I/II evaluated cirmtuzumab in combination with ibrutinib in patients with relapsed/refractory MCL. Credit: Nephron.